Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-14 00:16 | 2026-03-13 | XENE | Xenon Pharmaceuticals Inc. | KENNEY CHRISTOPHER JOHN | Officer | OPT+S | $55.23 | 1,410 | $77,867 | 7,069 |
| 2026-03-14 00:03 | 2026-03-12 | SRPT | Sarepta Therapeutics, Inc. | Mayo Stephen | Director | SELL | $17.02 | 7,239 | $123,208 | 1,765 |
| 2026-03-13 23:29 | 2026-03-11 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | Officer | OPT+S | $225.00 | 3,057 | $687,825 | 21,010 |
| 2026-03-13 22:22 | 2026-03-13 | CNTA | Centessa Pharmaceuticals plc | Weinhoff Gregory M | Officer | SELL | $26.33 | 73,196 | $1,927,134 | 65,925 |
| 2026-03-13 22:23 | 2026-03-13 | CNTA | Centessa Pharmaceuticals plc | Anderson Karen M. | Officer | OPT+S | $26.25 | 120,029 | $3,150,677 | 62,085 |
| 2026-03-13 21:46 | 2026-03-12 | CRNX | Crinetics Pharmaceuticals, Inc. | Vivaldi Coelho Rogerio | Director | SELL | $36.15 | 5,000 | $180,761 | 16,300 |
| 2026-03-13 21:20 | 2026-03-12 | PTCT | PTC THERAPEUTICS, INC. | Klein Matthew B. | Director, Officer | SELL | $64.08 | 2,662 | $170,581 | 396,920 |
| 2026-03-13 21:26 | 2026-03-11 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | OPT+S | $300.00 | 341 | $102,300 | 0 |
| 2026-03-13 21:28 | 2026-03-13 | ANIP | Ani Pharmaceuticals Inc. | Cook Meredith | Officer | SELL | $72.62 | 500 | $36,310 | 79,390 |
| 2026-03-13 21:28 | 2026-03-13 | ANIP | Ani Pharmaceuticals Inc. | Mutz Christopher | Officer | SELL | $71.64 | 3,162 | $226,526 | 91,309 |
| 2026-03-13 21:28 | 2026-03-11 | ANIP | Ani Pharmaceuticals Inc. | Rowland Thomas Andrew | Officer | SELL | $74.91 | 4,772 | $357,471 | 38,730 |
| 2026-03-13 20:46 | 2026-03-11 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Director | BUY | $19.35 | 2,000 | $38,700 | 13,500 |
| 2026-03-13 20:25 | 2026-03-13 | INDV | Indivior Pharmaceuticals, Inc. | Ryan Barbara | Director | BUY | $31.09 | 8 | $249 | 5,724 |
| 2026-03-13 12:00 | 2026-03-12 | ONCY | ONCOLYTICS BIOTECH INC | Kelly Jared | Director, Officer | BUY | $0.96 | 5,050 | $4,848 | 114,050 |
| 2026-03-13 12:00 | 2026-03-11 | ONCY | ONCOLYTICS BIOTECH INC | Parsons James T. | Director | BUY | $1.03 | 10,000 | $10,300 | 41,849 |
| 2026-03-12 20:12 | 2026-03-11 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $19.08 | 1,067 | $20,363 | 1,109,905 |
| 2026-03-12 20:25 | 2026-03-11 | NAMS | NewAmsterdam Pharma Co N.V. | LANGE LOUIS G | Director | SELL | $30.42 | 44,619 | $1,357,230 | 10,360 |
| 2026-03-12 21:20 | 2026-03-10 | PTCT | PTC THERAPEUTICS, INC. | Okey Stephanie | Director | OPT+S | $70.00 | 15,167 | $1,061,690 | 8,000 |
| 2026-03-12 23:55 | 2026-03-11 | BMRN | BIOMARIN PHARMACEUTICAL INC | Guyer Charles Greg | Officer | SELL | $60.46 | 16,486 | $996,744 | 79,953 |
| 2026-03-13 00:15 | 2026-03-10 | KRRO | Korro Bio, Inc. | Florence Anthony A. Jr. | 10% owner | BUY | $11.11 | 207,100 | $2,300,881 | 1,297,893 |
| 2026-03-13 00:15 | 2026-03-10 | KRRO | Korro Bio, Inc. | Walker Paul Edward | 10% owner | BUY | $11.11 | 207,100 | $2,300,881 | 1,297,893 |
| 2026-03-13 00:15 | 2026-03-10 | KRRO | Korro Bio, Inc. | Makhzoumi Mohamad | 10% owner | BUY | $11.11 | 207,100 | $2,300,881 | 1,297,893 |
| 2026-03-13 00:15 | 2026-03-10 | KRRO | Korro Bio, Inc. | Mathers Edward T | 10% owner | BUY | $11.11 | 207,100 | $2,300,881 | 1,297,893 |
| 2026-03-13 00:15 | 2026-03-10 | KRRO | Korro Bio, Inc. | BASKETT FOREST | 10% owner | BUY | $11.11 | 207,100 | $2,300,881 | 1,297,893 |
| 2026-03-13 00:15 | 2026-03-10 | KRRO | Korro Bio, Inc. | Chang Carmen | 10% owner | BUY | $11.11 | 207,100 | $2,300,881 | 1,297,893 |
| 2026-03-13 00:15 | 2026-03-10 | KRRO | Korro Bio, Inc. | New Enterprise Associates 17, L.P. | 10% owner | BUY | $11.11 | 207,100 | $2,300,881 | 1,297,893 |
| 2026-03-13 00:15 | 2026-03-10 | KRRO | Korro Bio, Inc. | SANDELL SCOTT D | 10% owner | BUY | $11.11 | 207,100 | $2,300,881 | 1,297,893 |
| 2026-03-13 00:15 | 2026-03-10 | KRRO | Korro Bio, Inc. | Yang Rick | 10% owner | BUY | $11.11 | 207,100 | $2,300,881 | 1,297,893 |
| 2026-03-12 20:56 | 2026-03-10 | STOK | Stoke Therapeutics, Inc. | Krainer Adrian R. | Director | SELL | $39.74 | 33,243 | $1,320,964 | 283,302 |
| 2026-03-12 20:57 | 2026-03-10 | STOK | Stoke Therapeutics, Inc. | TZIANABOS ARTHUR | Director, Officer | OPT+S | $40.00 | 4,355 | $174,214 | 31,339 |
| 2026-03-12 20:31 | 2026-03-10 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $5.67 | 8,000 | $45,360 | 62,405 |
| 2026-03-12 20:15 | 2026-03-10 | BBIO | BridgeBio Pharma, Inc. | Valantine Hannah | Director | OPT+S | $72.00 | 8,671 | $624,312 | 7,465 |
| 2026-03-12 10:05 | 2026-03-10 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Director | BUY | $21.84 | 2,000 | $43,670 | 38,415 |
| 2026-03-11 20:47 | 2026-03-09 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | Director, Officer | OPT+S | $19.17 | 36,766 | $704,657 | 339,392 |
| 2026-03-11 20:30 | 2026-03-09 | LQDA | Liquidia Corp | Moomaw Scott | Officer | OPT+S | $35.32 | 80,000 | $2,825,824 | 188,954 |
| 2026-03-11 20:18 | 2026-03-10 | IONS | IONIS PHARMACEUTICALS INC | Jenne Kyle | Officer | OPT+S | $75.85 | 37,277 | $2,827,326 | 11,714 |
| 2026-03-11 20:38 | 2026-03-09 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | OPT+S | $45.92 | 36,722 | $1,686,157 | 12,086 |
| 2026-03-11 20:35 | 2026-03-09 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Officer | SELL | $13.04 | 15,010 | $195,771 | 198,588 |
| 2026-03-11 20:34 | 2026-03-09 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | Officer | SELL | $13.01 | 16,477 | $214,379 | 121,510 |
| 2026-03-11 21:45 | 2026-03-09 | ORGO | Organogenesis Holdings Inc. | Driscoll Michael Joseph | Director | BUY | $2.67 | 10,000 | $26,688 | 225,707 |
| 2026-03-11 20:19 | 2026-03-09 | IONS | IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. | Officer | SELL | $75.25 | 10,148 | $763,662 | 62,211 |
| 2026-03-11 21:02 | 2026-02-26 | EDSA | Edesa Biotech, Inc. | Brooks Michael J | Officer | BUY | $1.57 | 2,000 | $3,140 | 226,870 |
| 2026-03-11 20:19 | 2026-03-09 | IONS | IONIS PHARMACEUTICALS INC | Monia Brett P | Director, Officer | OPT+S | $75.35 | 160,773 | $12,114,149 | 242,662 |
| 2026-03-11 20:10 | 2026-03-09 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Dieter David | Officer | SELL | $36.65 | 6,224 | $228,110 | 91,047 |
| 2026-03-11 20:33 | 2026-03-09 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Director | BUY | $11.21 | 2,000 | $22,420 | 7,450 |
| 2026-03-11 20:30 | 2026-03-10 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $539.71 | 9,500 | $5,127,274 | 130 |
| 2026-03-12 01:45 | 2026-03-09 | ORGO | Organogenesis Holdings Inc. | Leibowitz Arthur S | Director | BUY | $2.68 | 5,000 | $13,405 | 291,014 |
| 2026-03-12 00:25 | 2026-02-19 | EQ | Equillium, Inc. | Zedelmayer Christine | Officer | OPT+S | $1.76 | 185,937 | $328,104 | 91,444 |
| 2026-03-12 00:11 | 2026-03-09 | EQ | Equillium, Inc. | Zedelmayer Christine | Officer | OPT+S | $2.00 | 181,219 | $362,438 | 62,586 |
| 2026-03-11 23:20 | 2026-03-09 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Director, Officer | OPT+S | $60.32 | 281,269 | $16,966,512 | 14,731 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.